DMAC - DiaMedica Therapeutics Inc.

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 3.17

Open

$ 3.17

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 3.17 - $ 3.20

52 Week Range

$ 1.67 - $ 4.75

Volume

7,101

Average Volume

Market Cap

120.35M

Beta (5Y Monthly)

$ 1.06

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-19-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-14-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-28-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-10-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	03-14-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-11-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	03-10-2021	12-31-2020	10-K
15	11-04-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-13-2020	03-31-2020	10-Q
18	03-23-2020	12-31-2019	10-K
19	11-13-2019	09-30-2019	10-Q
20	08-13-2019	06-30-2019	10-Q
21	05-13-2019	03-31-2019	10-Q
22	03-19-2019	12-31-2018	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

DiaMedica Therapeutics Q1 2024 GAAP EPS $(...
05/08/2024 22:39:50

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...

Craig-Hallum Assumes DiaMedica Therapeutic...
04/24/2024 17:33:22

Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Targ...

DiaMedica Therapeutics Doses First Patient...
04/17/2024 20:08:51

Craig-Hallum Maintains Buy on DiaMedica Th...
03/21/2024 18:31:19

Craig-Hallum analyst Alexander Nowak maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target f...

Oppenheimer Reiterates Outperform on DiaMe...
03/21/2024 12:43:47

Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and lowers the pric...

Recap: DiaMedica Therapeutics Q4 Earnings
03/19/2024 21:25:11

DiaMedica Therapeutics FY23 EPS $(0.60) Vs...
03/19/2024 20:31:05

Financial ResultsResearch and development (R&D) expenses increased to $13.1 million for the year ended December 31, 2023, u...

DiaMedica Therapeutics Q3 EPS $(0.12) Beat...
11/13/2023 21:57:37

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate o...

Earnings Scheduled For November 13, 2023
11/13/2023 11:40:53

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr...

Earnings Outlook For DiaMedica Therapeutics
11/10/2023 17:02:09

DiaMedica Therapeutics Q2 EPS $(0.16) Beat...
08/14/2023 20:48:05

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate o...

Earnings Scheduled For August 14, 2023
08/14/2023 10:45:55

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per ...

Benzinga's Top Ratings Upgrades, Downgrade...
06/22/2023 15:02:26

Oppenheimer Upgrades DiaMedica Therapeutic...
06/22/2023 11:16:31

Oppenheimer analyst Francois Brisebois upgrades DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announce...

diamedica-raises-375m-via-equity-offering-aiding-development-activities-for-dm199

DiaMedica Raises $37.5M Via Equity Offerin...
06/21/2023 15:40:11

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide ...

DiaMedica Therapeutics Announces $37.5M Pr...
06/21/2023 12:42:03

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...

DiaMedica Therapeutics Announces That The ...
06/21/2023 12:16:48

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...

Diamedica Therapeutics Included In Respons...
05/22/2023 21:18:11

- 8K Filing

Filed On May 19, DiaMedica Therapeutics A ...
05/22/2023 21:17:44

On May 22, 2023, DiaMedica Therapeutics Inc. (the "Company") announced that the Company filed on May 19, 2023 a complet...

DiaMedica Therapeutics Q1 EPS $(0.20) Miss...
05/15/2023 20:32:38

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate...